BRIEF-FDA Approves Supplemental New Drug Application For Myrbetriq For Treatment Of Overactive Bladder Symptoms


May 7 (Reuters) – Astellas Pharma Inc:

* FDA APPROVES SUPPLEMENTAL NEW DRUG APPLICATION FOR MYRBETRIQ® (MIRABEGRON) FOR USE IN COMBINATION WITH SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER SYMPTOMS

* ASTELLAS PHARMA INC- SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) SUBMISSION WAS BASED ON DATA FROM GLOBAL PHASE 3 SYNERGY I, SYNERGY II AND BESIDE STUDIES Source text for Eikon: Further company coverage:



Source link

Leave a Reply

Your email address will not be published.